Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Bifidobacterium breve is a probiotic bacterium that has been studied for its potential to support or treat colitis, particularly inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn’s disease. Scientific evidence, while still emerging and not uniformly robust, suggests that B. breve may have beneficial effects in managing colitis symptoms and reducing inflammation in the gut.

Several animal studies have demonstrated that administration of B. breve can reduce colonic inflammation, modulate immune responses, and help restore the balance of gut microbiota disrupted during colitis. These effects are thought to be mediated through the production of short-chain fatty acids, enhancement of the intestinal barrier, and downregulation of pro-inflammatory cytokines. For example, studies using murine models of colitis have shown that B. breve supplementation can decrease disease severity and improve histological markers of inflammation.

In humans, clinical evidence is more limited but promising. Some small-scale randomized controlled trials and pilot studies have investigated the effects of B. breve, either alone or in combination with other probiotics, in patients with ulcerative colitis. Results indicate potential benefits in inducing or maintaining remission and improving symptoms, although findings are not always consistent, and larger, well-designed trials are needed to confirm efficacy.

Overall, the scientific foundation for using B. breve in colitis is moderate (rating: 3/5), with supportive preclinical data and some encouraging early clinical findings. However, it should not yet be considered a stand-alone therapy, and more research is necessary to establish standardized protocols and confirm long-term safety and effectiveness.

More about bifidobacterium breve
More about Colitis

Other ingredients used for Colitis

Other health conditions supported by bifidobacterium breve

Products containing bifidobacterium breve